{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:56:40Z","timestamp":1751021800103,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Janssen-Cilag GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40744-022-00484-3","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T15:22:20Z","timestamp":1662477740000},"page":"1435-1450","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ustekinumab Is Rapid-Acting and Is an Effective Long-Term Treatment for Patients with Active Psoriatic Arthritis: Real-World Evidence from the Non-interventional SUSTAIN Study"],"prefix":"10.1007","volume":"9","author":[{"given":"J\u00f6rg","family":"Wendler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6117-6769","authenticated-orcid":false,"given":"Nils","family":"Damann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marit","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Teicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Schuier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Schwenke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maren","family":"Sieburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"issue":"1","key":"484_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65\u201370.","journal-title":"Clin Med (Lond)"},{"key":"484_CR2","doi-asserted-by":"crossref","unstructured":"Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019;8.","DOI":"10.12688\/f1000research.19144.1"},{"issue":"7","key":"484_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2165\/00128071-200304070-00001","volume":"4","author":"H Zachariae","year":"2003","unstructured":"Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol. 2003;4(7):441\u20137.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"484_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/BOR.0000000000000152","volume":"27","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):118\u201326.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"484_CR5","first-page":"511","volume":"24","author":"JA Husted","year":"1997","unstructured":"Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol. 1997;24(3):511\u20137.","journal-title":"J Rheumatol"},{"issue":"12","key":"484_CR6","first-page":"680","volume":"35","author":"S Lee","year":"2010","unstructured":"Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35(12):680\u20139.","journal-title":"P T"},{"issue":"Suppl 1","key":"484_CR7","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","volume":"59","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(Suppl 1):i37\u201346.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"484_CR8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, et\u00a0al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"484_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et\u00a0al. Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"484_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Braun J, Dougados M, et\u00a0al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6\u201316.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"484_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","volume":"3","author":"JM Benson","year":"2011","unstructured":"Benson JM, Peritt D, Scallon BJ, et\u00a0al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535\u201345.","journal-title":"MAbs"},{"issue":"9894","key":"484_CR12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et\u00a0al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780\u20139.","journal-title":"Lancet"},{"issue":"6","key":"484_CR13","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, et\u00a0al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139.","journal-title":"Ann Rheum Dis"},{"key":"484_CR14","unstructured":"European Medicines Agency. Stelara: ustekinumab https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara. Accessed 03 Nov, 2021."},{"key":"484_CR15","unstructured":"Janssen Biotech Inc. Highlights of prescribing information: Stelara\u00ae (ustekinumab) injection, for subcutaneous or intravenous use. In.; 2012."},{"issue":"1","key":"484_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"484_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001002","volume":"5","author":"LC Coates","year":"2019","unstructured":"Coates LC, Strand V, Wilson H, et\u00a0al. Measurement properties of the minimal disease activity criteria for psoriatic arthritis. RMD Open. 2019;5(2): e001002.","journal-title":"RMD Open"},{"issue":"11","key":"484_CR18","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","volume":"80","author":"JS Smolen","year":"2021","unstructured":"Smolen JS, Siebert S, Korotaeva TV, et\u00a0al. Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. Ann Rheum Dis. 2021;80(11):1419\u201328.","journal-title":"Ann Rheum Dis"},{"key":"484_CR19","doi-asserted-by":"crossref","unstructured":"Iannone F, Santo L, Bucci R, et\u00a0al. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). Clin Rheumatol. 2018;37(3):667\u201375.","DOI":"10.1007\/s10067-018-3989-2"},{"issue":"1","key":"484_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","volume":"47","author":"JF Merola","year":"2017","unstructured":"Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(1):29\u201337.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"484_CR21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","volume":"178","author":"A Egeberg","year":"2018","unstructured":"Egeberg A, Ottosen MB, Gniadecki R, et\u00a0al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol. 2018;178(2):509\u201319.","journal-title":"Br J Dermatol"},{"issue":"10","key":"484_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","volume":"307","author":"K Reich","year":"2015","unstructured":"Reich K, Mrowietz U, Radtke MA, et\u00a0al. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. Arch Dermatol Res. 2015;307(10):875\u201383.","journal-title":"Arch Dermatol Res"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00484-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-022-00484-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-022-00484-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T16:56:56Z","timestamp":1701017816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-022-00484-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["484"],"URL":"https:\/\/doi.org\/10.1007\/s40744-022-00484-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"1 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The SUSTAIN study was sponsored and funded by Janssen-Cilag GmbH (Germany). External authors did not receive funding (except for participation as a study site). Janssen-Cilag GmbH (Germany) funded the journal\u2019s Rapid Service Fee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Medical writing support, funded by Janssen-Cilag GmbH (Germany), was provided by Joe\u00a0Pickering, PhD, from Mudskipper Business Limited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Medical Writing and Editorial Assistance"}},{"value":"J.W.: conception\/design of the study, data analysis and interpretation, drafting the manuscript, critical revision of the manuscript, final approval of manuscript; N.D.: data analysis and interpretation, compilation and review of manuscript; M.R.: data interpretation, compilation and review of manuscript; V.T.: review of manuscript; M.S.: conceptualization of the SUSTAIN study, contribution to study setup and review of manuscript; F.H.: review of manuscript; H.S.: review of manuscript; M.Si.: review of manuscript; F.B.: study design, data generation, review of manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"J\u00f6rg Wendler was an advisor and\/or received speakers\u2019 honoraria and\/or received grants and\/or participated in clinical trials of the following companies: AbbVie, Chugai, Janssen-Cilag GmbH, Novartis, Roche Pharma; Nils Damann, Marit R\u00f6cken, and Verena Teicher are employees of Janssen-Cilag\u00a0GmbH and hold stocks of Johnson & Johnson; Maximilian Schuier is an employee of Johnson & Johnson, holding stocks thereof; Frank Hamann, Holger Schwenke, and Maren Sieburg declare no competing interests; Frank\u00a0Behrens has received research grants and consultancy\/speaker fees from Janssen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All patients provided written informed consent, and the study was approved by the ethics commission of the Bavarian State Chambers of Physicians (Bayerische Landes\u00e4rztekammer). Written informed consent was obtained from all participants. The study was carried out in accordance with the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}